Abstract | BACKGROUND: METHODS: In this phase I, multicentre study, KW-2478 was administered intravenously over 1 h at doses ranging from 14 to 176 mg m(-2) once daily on days 1-5 of a 14-day cycle in a standard 3+3 design in 27 patients (22 with multiple myeloma and 5 with non-Hodgkin lymphoma). Patients enrolled had relapsed/refractory disease previously treated with ⩾2 regimens. RESULTS: There were no dose-limiting toxicities, thus the maximum-tolerated dose was not reached. KW-2478 was well tolerated and did not manifest significant retinal or ocular toxicity. The most common treatment-related adverse events were diarrhoea (33.3%), fatigue (29.6%), headache (25.9%), hypertension (22.2%), nausea (14.8%), vomiting (7.4%), and dizziness (7.4%). Plasma concentrations peaked at the end of infusion and decayed in a biphasic manner with a terminal half-life of ∼6 h. Target inhibition was inferred from the increase in Hsp70 levels in peripheral blood mononuclear cells at doses ⩾71 mg m(-2). Twenty-four of 25 (96%) evaluable patients showed stable disease, with five being free of disease progression for ⩾6 months. CONCLUSIONS: Preliminary clinical response data were encouraging and warrant further investigation of KW-2478 in combination regimens for relapsed/refractory B-cell malignancies.
|
Authors | K Yong, J Cavet, P Johnson, G Morgan, C Williams, D Nakashima, S Akinaga, H Oakervee, J Cavenagh |
Journal | British journal of cancer
(Br J Cancer)
Vol. 114
Issue 1
Pg. 7-13
(Jan 12 2016)
ISSN: 1532-1827 [Electronic] England |
PMID | 26695442
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- HSP90 Heat-Shock Proteins
- KW-2478
- Morpholines
|
Topics |
- Aged
- Female
- HSP90 Heat-Shock Proteins
(antagonists & inhibitors)
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Morpholines
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Multiple Myeloma
(drug therapy)
|